Kalaris Therapeutics filings document formal disclosures for a Nasdaq-listed clinical-stage biopharmaceutical company developing retinal-disease therapeutics. The record includes 8-K reports on operating and financial results, Regulation FD clinical presentations for TH103, material-event disclosures, capital-structure matters, and executive officer changes.
Proxy materials describe annual meeting and shareholder voting matters, while security disclosures identify Kalaris common stock under the KLRS ticker. Clinical disclosures focus on TH103 safety, tolerability, pharmacokinetics, early efficacy information, manufacturing updates, and the company's retinal-disease development plans.
Kalaris Therapeutics, Inc. is registering for resale up to 5,000,000 shares of its common stock, consisting of 4,200,000 outstanding shares held by selling stockholders and 800,000 shares issuable upon exercise of pre-funded warrants. The company will not receive proceeds from resales, but will receive cash if pre-funded warrants are exercised at an exercise price of $0.0001 per share. The registration implements registration rights granted in connection with a December 17, 2025 private placement in which the company raised aggregate gross proceeds of approximately $50.0 million through the sale of common stock and pre-funded warrants. Resales may occur from time to time in various manners described under the plan of distribution; certain exercise and beneficial ownership limits (a 4.99% default cap, up to 19.99% if elected) apply to the pre-funded warrants.
Kalaris Therapeutics, Inc. announced that Chief Financial Officer Matthew Gall will resign effective April 14, 2026. In connection with his departure, Brett Hagen, the current Chief Accounting Officer and principal accounting officer, will also serve as the company’s principal financial officer from the same date.
The filing outlines Mr. Hagen’s prior senior finance roles at several biopharmaceutical companies and his academic background in accounting and finance. It also notes that he has no family relationships with directors or officers, no related-party transactions requiring disclosure, and that his compensation arrangements remain unchanged.
Kalaris Therapeutics, Inc. is registering up to $350,000,000 of securities on a shelf, including an $100,000,000 program to sell common stock under a sales agreement.
The prospectus covers debt securities, common stock, preferred stock, subscription rights, warrants and units that may be offered "from time to time"; specific terms and distribution methods will be set forth in prospectus supplements. The company has an at-the-market sales agreement with TD Cowen that permits sales of up to $100,000,000 of common stock, with compensation up to 3.0%.
Kalaris Therapeutics, Inc. registers for resale up to 5,000,000 shares of its common stock, consisting of 4,200,000 outstanding shares and 800,000 shares issuable upon exercise of pre-funded warrants. The prospectus covers resales by the selling stockholders; the company will not receive proceeds from resales, although it would receive cash if pre-funded warrants are exercised at an exercise price of $0.0001 per share. The shares were issued in a private placement that generated approximately $50.0 million in gross proceeds at a price of $10.00 per share (and pre-funded warrants at $9.9999), and the registration statement was filed to satisfy registration rights. Shares outstanding were 22,928,303 as of February 28, 2026. The prospectus permits sales on Nasdaq or other methods described under "Plan of Distribution," and notes a Beneficial Ownership Limitation (default 4.99%, adjustable up to 19.99% with notice).
Kalaris Therapeutics Chief Accounting Officer Brett R. Hagen reported an open-market sale of 1,915 shares of common stock at $6.72 per share, leaving no directly held common shares after the transaction. On the prior day, he received a grant of stock options for 60,800 shares of common stock at an exercise price of $6.81 per share, expiring on March 18, 2036. According to the grant terms, 25% of the underlying shares vest on March 19, 2027, with the remainder vesting in equal monthly installments thereafter, subject to continuous service. A footnote clarifies that a previous filing overstated his beneficial ownership by 10 shares, from 1,925 to 1,915, and this has now been corrected.
Kalaris Therapeutics, Inc. (KLRS) officer Brett Roger Hagen gave notice of a proposed sale of 1,915 common shares, with an aggregate market value of $12,868.80 and an approximate sale date of March 20, 2026. Morgan Stanley Smith Barney LLC is listed as the broker. The reported acquisition history includes restricted stock vesting under a registered plan.
Kalaris Therapeutics director and officer Andrew Oxtoby received a stock option grant covering 222,000 shares of Common Stock. The option was granted as a compensation award with an exercise price of $6.8100 per share and expires on March 18, 2036.
The shares underlying the option vest over four years, with 25% vesting on March 19, 2027 and the remaining 75% vesting in equal monthly installments thereafter, subject to continuous service. Following this grant, Oxtoby holds 222,000 derivative securities directly.
Kalaris Therapeutics, Inc. reported that Chief Financial Officer Matthew Gall received a grant of stock options for 95,000 shares of common stock. The options carry an exercise price of $6.81 per share, expire on March 18, 2036, and vest over four years starting March 19, 2027.
Kalaris Therapeutics, Inc. reported that Chief Medical Officer Matthew Feinsod received a grant of stock options covering 135,000 shares of common stock. The options have an exercise price of $6.81 per share and expire on March 18, 2036.
According to the vesting terms, 25% of the underlying shares are scheduled to vest on March 19, 2027, with the remaining shares vesting in equal monthly installments over the following three years, subject to continuous service. After this grant, Feinsod holds options for 135,000 shares directly.
Kalaris Therapeutics, Inc., formerly AlloVir, has transformed into a clinical-stage biopharmaceutical company focused on prevalent retinal diseases after completing a merger with Legacy Kalaris on March 18, 2025. The company’s strategy centers on TH103, a novel anti‑VEGF fusion protein engineered for extended intraocular retention via high‑affinity binding to VEGF and heparan sulfate proteoglycans.
Initial Phase 1a data in neovascular age‑related macular degeneration showed a mean 10‑letter gain in visual acuity and strong fluid resolution after a single dose, with TH103 generally well tolerated aside from some intraocular inflammation that the company is addressing through manufacturing process refinements to lower host cell proteins. A Phase 1b/2 multiple‑dose study in nAMD is ongoing, with preliminary data expected in the first half of 2027, and Kalaris plans potential Phase 3 trials by year‑end 2027 plus indication expansion into diabetic eye disease, retinal vein occlusion and retinopathy of prematurity. The company reports an aggregate market value of non‑affiliate equity of $12.6 million as of June 30, 2025 and 22,928,303 common shares outstanding as of March 10, 2026, and highlights typical early‑stage biotech risks, including continued losses, substantial funding needs, heavy dependence on TH103 and Nasdaq “controlled company” status due to principal stockholder Samsara BioCapital.